- Recruiting
NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis
NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT04131309
Official Title: Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
First Posted : October 18, 2019
Click here to see details on ClinicalTrials.gov
EMN22 - European Myeloma Network (myeloma-europe.org)
Daratumumab : National Cancer Institute
Daratumumab : MedlinePlus Drug Information
Daratumumab and Hyaluronidase-fihj Injection: National Cancer Institute
Daratumumab and Hyaluronidase-fihj Injection: MedlinePlus Drug Information
Bortezomib : National Cancer Institute
Bortezomib : MedlinePlus Drug Information
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Drug: Daratumumab
Drug: Bortezomib Injection
Drug: Dexamethasone oral tablet
Locations
Europe
France
Greece
Italy
Netherlands